Skip to main content

Merck says experimental RSV treatment protected infants in trial, paving way for potential approval

Merck is discussing the study data with regulators worldwide, with a goal of making the treatment available for infants as early as the 2025 to 2026 RSV season.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.